Sagefield Capital’s Core Laboratories CLB Stock Holding History

Sagefield Capital’s Portfolio CLB Stock Details CLB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-162,845	Closed	-$3.79M	–	108
2023 Q2	$3.79M	Buy	+162,845	New	+$3.68M	0.81%	36

Other funds holding CLB

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

BTW

Boston Trust Walden Boston, Massachusetts $13.1B AUM 24.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

FAM

Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return

CAM

Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Sagefield Capital's CLB Position: Q3 2023 in Review

Sagefield Capital sold out of Core Laboratories (CLB) in Q3 2023, closing a stake of 162,845 shares — an estimated $3.79M sold.

Sagefield Capital first reported a position in CLB in Q2 2023 and held it in 1 quarter. The position peaked at $3.79M in Q2 2023. 178 funds tracked by Wall St. Rank hold CLB as of Q3 2023.

Sagefield Capital reported no remaining Core Laboratories position as of Q3 2023 after selling out during the quarter.
Sagefield Capital sold 162,845 Core Laboratories shares in Q3 2023, an estimated $3.79M.
Sagefield Capital first reported a position in Core Laboratories in Q2 2023 and held it in 1 quarter.
Sagefield Capital's Core Laboratories position peaked at $3.79M in Q2 2023.
178 funds tracked by Wall St. Rank held Core Laboratories as of Q3 2023.

Based on Sagefield Capital's 13F filing for Q3 2023, filed 14 Nov 2023.